AGA临床实践更新:急性肝卟啉症的诊断与管理专家综述
美国胃肠病协会(AGA)发布的急性肝卟啉症(AHP)最佳实践建议,涵盖筛查、诊断、急性发作治疗、预防性治疗及长期监测。推荐对15-50岁不明原因反复严重腹痛女性筛查AHP,随机尿δ-氨基乙酰丙酸和卟胆原为初筛,基因检测确诊,急性发作静脉血红素治疗,复发者预防性治疗,并长期监测肝病、肝癌和肾病。
要点
- 15-50岁女性不明原因反复严重腹痛应考虑筛查AHP。
- 随机尿δ-氨基乙酰丙酸、卟胆原和肌酐为初筛,基因检测确诊。
- 急性发作需住院者应每日静脉血红素,复发者考虑预防治疗。
核心结论
- AHP应纳入不明原因反复严重腹痛的鉴别诊断,尤其15-50岁女性。
- 初筛用随机尿δ-氨基乙酰丙酸和卟胆原校正肌酐,基因检测确诊。
- 急性发作治疗包括停用卟啉原性药物、静脉血红素及对症支持。
- 复发发作(每年4次或以上)者考虑预防性血红素或givosiran。
- AHP患者需长期监测肝病、肝癌和慢性肾病。
研究设计与样本
- 本专家综述由AGA研究所临床实践更新委员会(CPUC)和AGA理事会委托并批准。
- 建议基于已发表文献回顾和专家意见,未进行系统评价,故不提供正式证据质量或推荐强度分级。
主要发现
- AHP为罕见血红素代谢先天缺陷,包括急性间歇性卟啉症、遗传性粪卟啉症、变异型卟啉症和δ-氨基乙酰丙酸脱水酶严重缺乏所致卟啉症。
- 急性间歇性卟啉症最常见,有症状患者估计患病率约十万分之一。
- 主要临床表现为严重疼痛发作,通常为腹部和全身性,无腹膜刺激征或横断面影像异常。
- 急性发作主要见于育龄期女性。
- AHP与慢性症状及系统性动脉高血压、慢性肾病和肝病、肝细胞癌长期风险相关。
关键数值与推荐
- 最佳实践建议1:15-50岁女性,初始检查后不明原因反复严重腹痛,应考虑筛查AHP。
- 最佳实践建议2:AHP初诊应通过随机尿样生化检测δ-氨基乙酰丙酸、卟胆原和肌酐。
- 最佳实践建议3:生化检测阳性者应使用基因检测确认AHP诊断。
- 最佳实践建议4:需住院的严重AHP急性发作应每日静脉给予血红素,最好经高流量中心静脉。
- 最佳实践建议5:急性发作管理除静脉血红素外,应包括疼痛控制、止吐、管理系统性动脉高血压、心动过速、低钠血症和低镁血症(如有)。
临床怎么用
- 对15-50岁女性不明原因反复严重腹痛,应考虑筛查AHP。
- 疑似AHP时,检测随机尿δ-氨基乙酰丙酸、卟胆原和肌酐。
- 确诊AHP后,应进行基因检测明确类型。
- 急性发作需住院者,每日静脉血红素治疗,并处理疼痛、高血压、心动过速和电解质紊乱。
- 复发发作(每年4次或以上)者,考虑预防性血红素或givosiran。
局限性
- 本专家综述未进行系统评价,故不提供正式证据质量或推荐强度分级。
- 建议基于已发表文献回顾和专家意见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: The acute hepatic porphyrias (AHP) are rare, inborn errors of heme-metabolism and include acute intermittent porphyria, hereditary coproporphyria, variegate porphyria, and porphyria due to severe deficiency of 5-aminolevulinic acid dehydratase. Acute intermittent porphyria is the most common type of AHP, with an estimated prevalence of patients with symptoms of approximately 1 in 100,000. The major clinical presentation involves attacks of severe pain, usually abdominal and generalized, without peritoneal signs or abnormalities on cross-sectional imaging. Acute attacks occur mainly in women in their childbearing years. AHP should be considered in the evaluation of all patients, and especially women aged 15-50 years with recurrent severe abdominal pain not ascribable to common causes. The screening tests of choice include random urine porphobilinogen and δ-aminolevulinic acid corrected to creatinine. All patients with elevations in urinary porphobilinogen and/or δ-aminolevulinic acid should initially be presumed to have AHP. The cornerstones of management include discontinuation of porphyrinogenic drugs and chemicals, administration of oral or intravenous dextrose and intravenous hemin, and use of analgesics and antiemetics. Diagnosis of AHP type can be confirmed after initial treatment by genetic testing for pathogenic variants in HMBS, CPOX, PPOX, and ALAD genes. AHP is also associated with chronic symptoms and long-term risk of systemic arterial hypertension, chronic renal and liver disease, and hepatocellular carcinoma. Patients who have recurrent acute attacks (4 or more per year) should be considered for prophylactic therapy with intravenous hemin or subcutaneous givosiran. Liver transplantation is curative and reserved for patients with intractable symptoms who have failed other treatment options. METHODS: This expert review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology. These Best Practice Advice (BPA) statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these BPA statements do not carry formal ratings of the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: Women aged 15-50 years with unexplained, recurrent severe abdominal pain without a clear etiology after an initial workup should be considered for screening for an AHP. BEST PRACTICE ADVICE 2: Initial diagnosis of AHP should be made by biochemical testing measuring δ-aminolevulinic acid, porphobilinogen, and creatinine on a random urine sample. BEST PRACTICE ADVICE 3: Genetic testing should be used to confirm the diagnosis of AHP in patients with positive biochemical testing. BEST PRACTICE ADVICE 4: Acute attacks of AHP that are severe enough to require hospital admission should be treated with intravenous hemin, given daily, preferably into a high-flow central vein. BEST PRACTICE ADVICE 5: In addition to intravenous hemin, management of acute attacks of AHP should include pain control, antiemetics, management of systemic arterial hypertension, tachycardia, and hyponatremia, and hypomagnesemia, if present. BEST PRACTICE ADVICE 6: Patients should be counseled to avoid identifiable triggers that may precipitate acute attacks, such as alcohol and porphyrinogenic medications. BEST PRACTICE ADVICE 7: Prophylactic heme therapy or givosiran, administered in an outpatient setting, should be considered in patients with recurrent attacks (4 or more per year). BEST PRACTICE ADVICE 8: Liver transplantation for AHP should be limited to patients with intractable symptoms and significantly decreased quality of life who are refractory to pharmacotherapy. BEST PRACTICE ADVICE 9: Patients with AHP should be monitored annually for liver disease. BEST PRACTICE ADVICE 10: Patients with AHP, regardless of the severity of symptoms, should undergo surveillance for hepatocellular carcinoma, beginning at age 50 years, with liver ultrasound every 6 months. BEST PRACTICE ADVICE 11: Patients with AHP on treatment should undergo surveillance for chronic kidney disease annually with serum creatinine and estimated glomerular filtration rate. BEST PRACTICE ADVICE 12: Patients should be counseled on the chronic and long-term complications of AHP, including neuropathy, chronic kidney disease, hypertension, and hepatocellular carcinoma, and need for long-term monitoring.
引用
- Wang B, Bonkovsky HL, Lim JK, et al. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology. 2023. PMID: 36642627. doi:10.1053/j.gastro.2022.11.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。